Video transcript: Advances in treatment for cancer have greatly improved survivability when the cancer is caught early. However, despite global spending of over $100
MIAMI, FL — Miami-based Emerging Growth has invited medical-imaging company Imagion Biosystems (ASX: IBX) to present at the next Emerging Growth Conference on October 23,
Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2. Abstract: MagSense is a
Earlier this month, our own Bob Proulx, Executive Chairman of Imagion Biosystems, had the opportunity to join Stuart Roberts on Pitt Street Research’s podcast Stocks
Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
Bob Proulx sat down with Rozalina Sarkezians, Managing Director & Founder of Health Industry Hub, for a chat about Imagion Biosystem’s work developing our breakthrough